Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics
The Fanconi Anemia (FA) pathway consists of proteins involved in repairing DNA damage, including interstrand cross-links (ICLs). The pathway contains an upstream multiprotein core complex that mediates the monoubiquitylation of the FANCD2 and FANCI heterodimer, and a downstream pathway that converge...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Anemia |
| Online Access: | http://dx.doi.org/10.1155/2012/481583 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552614127992832 |
|---|---|
| author | Chelsea Jenkins Jenny Kan Maureen E. Hoatlin |
| author_facet | Chelsea Jenkins Jenny Kan Maureen E. Hoatlin |
| author_sort | Chelsea Jenkins |
| collection | DOAJ |
| description | The Fanconi Anemia (FA) pathway consists of proteins involved in repairing DNA damage, including interstrand cross-links (ICLs). The pathway contains an upstream multiprotein core complex that mediates the monoubiquitylation of the FANCD2 and FANCI heterodimer, and a downstream pathway that converges with a larger network of proteins with roles in homologous recombination and other DNA repair pathways. Selective killing of cancer cells with an intact FA pathway but deficient in certain other DNA repair pathways is an emerging approach to tailored cancer therapy. Inhibiting the FA pathway becomes selectively lethal when certain repair genes are defective, such as the checkpoint kinase ATM. Inhibiting the FA pathway in ATM deficient cells can be achieved with small molecule inhibitors, suggesting that new cancer therapeutics could be developed by identifying FA pathway inhibitors to treat cancers that contain defects that are synthetic lethal with FA. |
| format | Article |
| id | doaj-art-04fa66391eed43e3be01ed4885f7c520 |
| institution | Kabale University |
| issn | 2090-1267 2090-1275 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Anemia |
| spelling | doaj-art-04fa66391eed43e3be01ed4885f7c5202025-02-03T05:58:10ZengWileyAnemia2090-12672090-12752012-01-01201210.1155/2012/481583481583Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer TherapeuticsChelsea Jenkins0Jenny Kan1Maureen E. Hoatlin2Department of Biochemistry and Molecular Biology, Oregon Health and Science University, 3181 SW Sam Jackson Parkway, Portland, OR 97239, USADepartment of Biochemistry and Molecular Biology, Oregon Health and Science University, 3181 SW Sam Jackson Parkway, Portland, OR 97239, USADepartment of Biochemistry and Molecular Biology, Oregon Health and Science University, 3181 SW Sam Jackson Parkway, Portland, OR 97239, USAThe Fanconi Anemia (FA) pathway consists of proteins involved in repairing DNA damage, including interstrand cross-links (ICLs). The pathway contains an upstream multiprotein core complex that mediates the monoubiquitylation of the FANCD2 and FANCI heterodimer, and a downstream pathway that converges with a larger network of proteins with roles in homologous recombination and other DNA repair pathways. Selective killing of cancer cells with an intact FA pathway but deficient in certain other DNA repair pathways is an emerging approach to tailored cancer therapy. Inhibiting the FA pathway becomes selectively lethal when certain repair genes are defective, such as the checkpoint kinase ATM. Inhibiting the FA pathway in ATM deficient cells can be achieved with small molecule inhibitors, suggesting that new cancer therapeutics could be developed by identifying FA pathway inhibitors to treat cancers that contain defects that are synthetic lethal with FA.http://dx.doi.org/10.1155/2012/481583 |
| spellingShingle | Chelsea Jenkins Jenny Kan Maureen E. Hoatlin Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics Anemia |
| title | Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics |
| title_full | Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics |
| title_fullStr | Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics |
| title_full_unstemmed | Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics |
| title_short | Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics |
| title_sort | targeting the fanconi anemia pathway to identify tailored anticancer therapeutics |
| url | http://dx.doi.org/10.1155/2012/481583 |
| work_keys_str_mv | AT chelseajenkins targetingthefanconianemiapathwaytoidentifytailoredanticancertherapeutics AT jennykan targetingthefanconianemiapathwaytoidentifytailoredanticancertherapeutics AT maureenehoatlin targetingthefanconianemiapathwaytoidentifytailoredanticancertherapeutics |